Treosulfan-based conditioning and Rapamycin-base GvHD prophylaxis prior to un-manipulated allogeneic haematopoietic stem cell transplantation from a mismatched donor in patients with high risk haematological malignancies.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2015
At a glance
- Drugs Sirolimus (Primary) ; Antithymocyte globulin; Fludarabine; Mycophenolic acid; Rituximab; Treosulfan
- Indications Acute myeloid leukaemia; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Follicular lymphoma; Graft-versus-host disease; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T cell lymphoma; Transplant rejection
- Focus Adverse reactions
- Acronyms TrRaMM
- 05 Jan 2013 Planned number of patients changed from 45 to 85 as reported by European Clinical Trials Database record.
- 26 Aug 2011 New trial record